Financial Report: Merck

Merck
 
4Q Revenues: $10.2 billion (-3%)

4Q Earnings: $976 million (earnings were $7.3 billion 4Q14)

FY Revenues: $39.5 billion (-6%)

FY Earnings: $4.4 billion (earnings were $11.9 billion FY14)

Comments: Revenues include a 7% negative impact from foreign exchange and 3% favorable impact from acquisitions and divestitures, primarily the acquisition of Cubist Pharmaceuticals. Januvia sales were down 12% to $1.4 billion likely due to a recent FDA safety alert about risk of joint pain, as well as the timing of purchases, according to the company. Sales of Remicade decreased 29% to $396 million due to loss of exclusivity and the impact of competition. Sales of Singulair, Zostavax, and Nasonex were all down 14% in the quarter. HPV vaccine Gardasil sales increased 40% to $497 million due to increased government purchases in the U.S. Keytruda performed well in the quarter with sales of $214 million.